Q&A with Dr. Richard Scheyer: Novel Approaches to Confirming CNS Penetration and Target Engagement
Richard Scheyer, MD, Vice President, Medical Affairs at Medpace answers some questions about his upcoming presentation about CNS-targeted therapies at DIA 2018.
How Rare Diseases Are Showing the Way Toward Precision Medicine – Part 3
In our previous post, we discussed the approaches to help you identify, enroll and retain rare disease populations in clinical trials. Once the right patients…